Literature DB >> 16226931

Heart failure in African Americans.

Clyde W Yancy1.   

Abstract

The demographics of the United States are changing, and in the next few decades there will no longer be a racial/ethnic majority population. Increased awareness of cardiovascular disease (CVD) in special populations is warranted as these populations increase. Heart failure carries a substantial burden on those affected, particularly African Americans, who have a disproportionate burden of heart disease. Current treatments for heart failure include angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin II-receptor antagonists, and vasodilating agents. This review discusses the unique characteristics of CVD in African Americans and addresses the need for targeted treatments to reduce the excess burden found in this population.

Entities:  

Mesh:

Year:  2005        PMID: 16226931     DOI: 10.1016/j.amjcard.2005.07.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  37 in total

1.  Isosorbide dinitrate and hydralazine as therapy for African Americans with heart failure; a failed paradigm?

Authors:  Clyde W Yancy; Arthur Feldman
Journal:  Clin Transl Sci       Date:  2009-08       Impact factor: 4.689

Review 2.  Race-related differences in heart failure therapies: simply black and white or shades of grey?

Authors:  Gautam R Shroff; Anne L Taylor; Monica Colvin-Adams
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

3.  Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation.

Authors:  Thomas P Cappola; Scot J Matkovich; Wei Wang; Derek van Booven; Mingyao Li; Xuexia Wang; Liming Qu; Nancy K Sweitzer; James C Fang; Muredach P Reilly; Hakon Hakonarson; Jeanne M Nerbonne; Gerald W Dorn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-19       Impact factor: 11.205

Review 4.  Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

5.  Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.

Authors:  Mostafa El-Refai; Tara Hrobowski; Edward L Peterson; Karen Wells; John A Spertus; L Keoki Williams; David E Lanfear
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2015-09       Impact factor: 2.160

6.  Fish intake and the risk of incident heart failure: the Women's Health Initiative.

Authors:  Rashad J Belin; Philip Greenland; Lisa Martin; Albert Oberman; Lesley Tinker; Jennifer Robinson; Joseph Larson; Linda Van Horn; Donald Lloyd-Jones
Journal:  Circ Heart Fail       Date:  2011-05-24       Impact factor: 8.790

7.  Short-term trends in heart failure-related hospitalizations in a high-risk state.

Authors:  Uchechukwu K A Sampson; Baqar A Husaini; Van A Cain; Zahid Samad; Eiman C Jahangir; Robert S Levine
Journal:  South Med J       Date:  2013-02       Impact factor: 0.954

8.  Racial differences in incident heart failure among young adults.

Authors:  Kirsten Bibbins-Domingo; Mark J Pletcher; Feng Lin; Eric Vittinghoff; Julius M Gardin; Alexander Arynchyn; Cora E Lewis; O Dale Williams; Stephen B Hulley
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

9.  Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study.

Authors:  Deepak K Gupta; Amil M Shah; Davide Castagno; Madoka Takeuchi; Laura R Loehr; Ervin R Fox; Kenneth R Butler; Thomas H Mosley; Dalane W Kitzman; Scott D Solomon
Journal:  JACC Heart Fail       Date:  2013-04       Impact factor: 12.035

10.  Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study.

Authors:  Steven C Hunt; Wei Chen; Jeffrey P Gardner; Masayuki Kimura; Sathanur R Srinivasan; John H Eckfeldt; Gerald S Berenson; Abraham Aviv
Journal:  Aging Cell       Date:  2008-05-02       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.